SCHEMBL1052202

SCHEMBL1052202

COC(=O)c1cc(N)c(OC)c(OC(C)=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ TSHR P16473 2/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ USP2 O75604 1/20 0.46
▸ KDM4E B2RXH2 4/20 0.45
▸ MAPT P10636 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ GLA P06280 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ CASP1 P29466 1/20 0.45
▸ CASP7 P55210 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ TOP1 P11387 3/20 0.44
▸ POLB P06746 2/20 0.43
▸ TUBB4A P04350 1/20 0.43
▸ TUBB P07437 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9333497 0.87 TSHR (0.56) SMN1; SMN2TSHRUSP2KDM4EMAPT
SCHEMBL1988431 0.86 TSHR (0.55) SMN1; SMN2TSHRPKMRAB9AUSP2
SCHEMBL3778844 0.83 TOP1 (0.60) SMN1; SMN2TSHRNPC1PKMRAB9A
SCHEMBL5220471 0.83 KDM4E (0.56) SMN1; SMN2TSHRNPC1PKMRAB9A
SCHEMBL1052229 0.78 TPMT (0.54) SMN1; SMN2NPC1PKMRAB9AKDM4E
SCHEMBL30079619 0.76 TPMT (0.51) SMN1; SMN2TSHRUSP2KDM4EMAPT
SCHEMBL7374627 0.75 LMNA (0.58) SMN1; SMN2TSHRALDH1A1TUBB4ATUBB
SCHEMBL18031417 0.75 KDM4E (0.53) SMN1; SMN2TSHRNPC1PKMRAB9A
SCHEMBL31059012 0.75 LMNA (0.58) SMN1; SMN2TSHRALDH1A1TUBB4ATUBB
SCHEMBL30418756 0.75 KDM4E (0.53) SMN1; SMN2TSHRNPC1PKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872014-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-01-18 — — US disclosed
EP-1648455-A4 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2009-03-04 — — EP disclosed
US-20070032515-A1 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2007-02-08 — — US disclosed
EP-1648455-A2 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-04-26 — — EP disclosed
WO-2005009389-A2 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032515-A1 Anaplastic lymphoma kinase modulators and methods of use ALK, MALT1, BCL6 SMN1; SMN2 3299/4885TSHR 3172/4885NPC1 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback